Glycobond develops and produces proprietary carbohydrate-binding reagents for use in diagnostics.


It is well known that carbohydrate structures that are attached to proteins in the body undergo specific changes during disease processes such as cancer and inflammation. Glycobond uses recombinant technology to produce carbohydrate-binding peptides with defined specificities for use primarily in diagnosis and monitoring of liver disesases and cancer.

Our first product is an assay for detecting primary liver cancer at an early stage.